Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery

Abstract

Ketorolac tromethamine was statistically significantly better than nepafenac in terms of patient satisfaction, compliance, and postoperative pain control.

Pharmacology, clinical efficacy and safety of nepafenac ophthalmic suspension

“…When amfenac was added to both cell lines, a statistically significant reduction in proliferation was observed, supporting the hypothesis that a COX-2 inhibitor can control the malignancy of certain types of tumors [21,22]. In recent years, numerous studies have been conducted in humans to analyze the safety and efficacy of nepafenac and to better understand the ability of topical NSAIDs to reach various tissues in the eye [3,8,10,11,[23][24][25][26][27]. NSAIDs are often used both before and after cataract surgery.…”

“…A higher incidence of posterior capsule opacification was reported in the nepafenac group. Statistically, ketorolac was slightly better in terms of patient compliance, satisfaction and postoperative pain control [25].…”

“…To compare ketorolac 0.4% with nepafenac 0.1% after cataract surgery, a prospective double-masked clinical trial by Duong and colleagues enrolled 183 patients (193 eyes) with visually significant cataract [25]. Patients were instructed to instill the respective medication in the eye undergoing surgery for 3 days preoperatively: one drop ketorolac four-times daily and one drop nepafenac three-times daily, and continue with the regimen for 7 days after surgery.…”

Postoperative Pain After Laser Refractive Surgery

“…For example, nepafenac is described more, less, or equally effective to ketorolac. 67,[80][81][82] In their review, Faktorovich and Melwani found 23 prospective and randomized studies that included NSAIDs, anesthetics, opiates, acetaminophen, gabapentin, and pregabalin for pain control after PRK surgery. They concluded that although the efficacy of drugs prone to be similar, tetracaine (1%) and nepafenac (0.1%) tended to have the most analgesic effect showing the lowest P-values when compared with placebo.…”

“…64 Nepafenac: Recent prospective randomized double-masked trials found nepafenac (0.1%) has satisfactory analgesic properties. [81][82][83] A randomized, double-masked, clinical trial, showed that nepafenac (0.03% and 0.1%) were effective for treatment of pain and photophobia in patients undergoing PRK surgery. 84 However, this drug is not approved yet by the FDA for treatment of postrefractive surgery pain.…”